Dalbavancin:novel candidate for COVID-19 treatment  

作　　者：Markus Hoffmann Yeonhwa Jin Stefan Pohlmann 

机构地区：[1]Infection Biology Unit,German Primate Center,37077 Göttingen,Germany [2]Faculty of Biology and Psychology,Georg-August-University Göttingen,37073 Göttingen,Germany

出　　处：《Cell Research》2021年第3期243-244,共2页细胞研究（英文版）

摘　　要：Antivirals approved for treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection and the associated coronavirus disease 2019(COVID-19)are largely lacking.In a recent study in Cell Research,Wang et al.show that the clinically proven antibiotic dalbavancin blocks SARS-CoV-2 binding to its receptor ACE2 and reduces viral spread and pathogenesis in animal models.

关 键 词：ACE2 al. ACUTE 

分 类 号：R978.7[医药卫生—药品]